Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q4 EPS of $0.03, $0.47 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $31.5 million versus the consensus estimate of $20.35 million.

Financial Guidance

Management reiterated its 2023 financial guidance including:

• Anticipated DANYELZA® net product revenues of $60-$65 million;
• Anticipated operating expenses of $115-120 million;
• Anticipated total annual cash burn of $50-55 million; and
• Cash and cash equivalents anticipated to support operations as currently planned into the first quarter of 2026.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.